Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy

Sara Gianella; Vincent C. Marconi; Baiba Berzins; Constance A. Benson; Paul Sax; Carl J. Fichtenbaum; Timothy Wilkin; Millie Vargas; Qianqian Deng; Michelli F. Oliveira; Carlee Moser; Babafemi O. Taiwo

doi:10.1097/QAI.0000000000001863

Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy

Sara Gianella^*, Vincent C. Marconi, Baiba Berzins, Constance A. Benson^*, Paul Sax, Carl J. Fichtenbaum, Timothy Wilkin, Millie Vargas^*, Qianqian Deng^*, Michelli F. Oliveira^*, Carlee Moser, Babafemi O. Taiwo

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Letter › peer-review

13 Scopus citations

Original language	English (US)
Pages (from-to)	E112-E114
Journal	Journal of Acquired Immune Deficiency Syndromes
Volume	79
Issue number	5
DOIs	https://doi.org/10.1097/QAI.0000000000001863
State	Published - Dec 15 2018

Funding

B.O.T. has served as a paid consultant to ViiV, Gilead, and Janssen and on the Clinical Care Options speakers bureau and has received grant funding to his institution from ViiV/GlaxoS-mithKline (GSK). V.C.M., C.J.F., C.A.B., T.W., have received grant funding for this study to their institutions through Northwestern University from ViiV/GSK. The remaining authors have no funding or conflicts of interest to disclose. Supported by an Investigator Sponsored Study grant ?Virologic Activity of DTG +3TC in the Genital Compartment: Substudy of ASPIRE and A5353? from ViiV Healthcare to Northwestern University. ViiV Healthcare/GlaxoSmithKline provided funding and study drugs. Additional support was provided from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636, and UM1 AI106701, the San Diego Center for AIDS Research Translational Virology Core (P30AI036214) as well as the Third Coast Center for AIDS Research (P30AI117943), and Emory Center for AIDS Research (P30AI050409). Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico (CNPq)-Brazil. Supported by an Investigator Sponsored Study grant “Virologic Activity of DTG +3TC in the Genital Compartment: Substudy of ASPIRE and A5353” from ViiV Healthcare to Northwestern University. ViiV Healthcare/GlaxoSmithKline provided fund-ing and study drugs. Additional support was provided from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636, and UM1 AI106701, the San Diego Center for AIDS Research Translational Virology Core (P30AI036214) as well as the Third Coast Center for AIDS Research (P30AI117943), and Emory Center for AIDS Research (P30AI050409). Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-Brazil.

ASJC Scopus subject areas

Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/QAI.0000000000001863

Cite this

@article{d975144ec19a441db1f338010bd30d87,

title = "Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy",

author = "Sara Gianella and Marconi, {Vincent C.} and Baiba Berzins and Benson, {Constance A.} and Paul Sax and Fichtenbaum, {Carl J.} and Timothy Wilkin and Millie Vargas and Qianqian Deng and Oliveira, {Michelli F.} and Carlee Moser and Taiwo, {Babafemi O.}",

note = "Funding Information: B.O.T. has served as a paid consultant to ViiV, Gilead, and Janssen and on the Clinical Care Options speakers bureau and has received grant funding to his institution from ViiV/GlaxoS-mithKline (GSK). V.C.M., C.J.F., C.A.B., T.W., have received grant funding for this study to their institutions through Northwestern University from ViiV/GSK. The remaining authors have no funding or conflicts of interest to disclose. Funding Information: Supported by an Investigator Sponsored Study grant ?Virologic Activity of DTG +3TC in the Genital Compartment: Substudy of ASPIRE and A5353? from ViiV Healthcare to Northwestern University. ViiV Healthcare/GlaxoSmithKline provided funding and study drugs. Additional support was provided from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636, and UM1 AI106701, the San Diego Center for AIDS Research Translational Virology Core (P30AI036214) as well as the Third Coast Center for AIDS Research (P30AI117943), and Emory Center for AIDS Research (P30AI050409). Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico (CNPq)-Brazil. Funding Information: Supported by an Investigator Sponsored Study grant “Virologic Activity of DTG +3TC in the Genital Compartment: Substudy of ASPIRE and A5353” from ViiV Healthcare to Northwestern University. ViiV Healthcare/GlaxoSmithKline provided fund-ing and study drugs. Additional support was provided from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636, and UM1 AI106701, the San Diego Center for AIDS Research Translational Virology Core (P30AI036214) as well as the Third Coast Center for AIDS Research (P30AI117943), and Emory Center for AIDS Research (P30AI050409). Conselho Nacional de Desenvolvimento Cient{\'i}fico e Tecnol{\'o}gico (CNPq)-Brazil.",

year = "2018",

month = dec,

day = "15",

doi = "10.1097/QAI.0000000000001863",

language = "English (US)",

volume = "79",

pages = "E112--E114",

journal = "Journal of Acquired Immune Deficiency Syndromes",

issn = "1525-4135",

publisher = "Wolters Kluwer Health",

number = "5",

}

TY - JOUR

T1 - Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy

AU - Gianella, Sara

AU - Marconi, Vincent C.

AU - Berzins, Baiba

AU - Benson, Constance A.

AU - Sax, Paul

AU - Fichtenbaum, Carl J.

AU - Wilkin, Timothy

AU - Vargas, Millie

AU - Deng, Qianqian

AU - Oliveira, Michelli F.

AU - Moser, Carlee

AU - Taiwo, Babafemi O.

N1 - Funding Information: B.O.T. has served as a paid consultant to ViiV, Gilead, and Janssen and on the Clinical Care Options speakers bureau and has received grant funding to his institution from ViiV/GlaxoS-mithKline (GSK). V.C.M., C.J.F., C.A.B., T.W., have received grant funding for this study to their institutions through Northwestern University from ViiV/GSK. The remaining authors have no funding or conflicts of interest to disclose. Funding Information: Supported by an Investigator Sponsored Study grant ?Virologic Activity of DTG +3TC in the Genital Compartment: Substudy of ASPIRE and A5353? from ViiV Healthcare to Northwestern University. ViiV Healthcare/GlaxoSmithKline provided funding and study drugs. Additional support was provided from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636, and UM1 AI106701, the San Diego Center for AIDS Research Translational Virology Core (P30AI036214) as well as the Third Coast Center for AIDS Research (P30AI117943), and Emory Center for AIDS Research (P30AI050409). Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico (CNPq)-Brazil. Funding Information: Supported by an Investigator Sponsored Study grant “Virologic Activity of DTG +3TC in the Genital Compartment: Substudy of ASPIRE and A5353” from ViiV Healthcare to Northwestern University. ViiV Healthcare/GlaxoSmithKline provided fund-ing and study drugs. Additional support was provided from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636, and UM1 AI106701, the San Diego Center for AIDS Research Translational Virology Core (P30AI036214) as well as the Third Coast Center for AIDS Research (P30AI117943), and Emory Center for AIDS Research (P30AI050409). Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-Brazil.

PY - 2018/12/15

Y1 - 2018/12/15

UR - http://www.scopus.com/inward/record.url?scp=85056322586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056322586&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000001863

DO - 10.1097/QAI.0000000000001863

M3 - Letter

C2 - 30383591

AN - SCOPUS:85056322586

SN - 1525-4135

VL - 79

SP - E112-E114

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

IS - 5

ER -

Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this